Laserfiche WebLink
<br />C-9 <br /> <br /> <br />regulation covered by subsection F.1 or oppose specific portions of such <br />legislation or regulation covered by subsections F.2-3. <br />5. Janssen shall provide notice of the prohibitions in subsection F to all employees <br />engaged in Lobbying; shall incorporate the prohibitions in subsection F into trainings <br />provided to Janssen employees engaged in Lobbying; and certify to the State of <br />Washington that it has provided such notice and trainings to Janssen employees <br />engaged in Lobbying. <br />G. Ban on Prescription Savings Programs <br />1. Janssen shall not directly or indirectly offer any discounts, coupons, rebates, or other <br />methods which have the effect of reducing or eliminating a patient’s co-payments or <br />the cost of prescriptions (e.g., free trial prescriptions) for any Opioid Product. <br />2. Janssen shall not directly or indirectly provide financial support to any Third Party <br />for discounts, coupons, rebates, or other methods which have the effect of reducing <br />or eliminating a patient’s co-payments or the cost of prescriptions (e.g., free trial <br />prescriptions) for any Opioid Product. <br />3. Janssen shall not directly or indirectly assist patients, Health Care Providers, or <br />pharmacies with the claims and/or prior authorization process required for third- <br />party payors to approve payment for any Opioid Product. <br />H. General Terms <br />1. Janssen shall not make any written or oral statement about Opioids or any Opioid <br />Product that is unfair, false, misleading, or deceptive as defined under the law of <br />Washington. For purposes of this paragraph, “Opioid Product” shall also include <br />methadone and other substances when used exclusively to treat opioid abuse, <br />addiction, or overdose. <br />2. Janssen shall not represent that Opioids or any Opioid Product(s) have approvals, <br />characteristics, uses, benefits, or qualities that they do not have. For purposes of this <br />paragraph, “Opioid Product” shall also include methadone and other substances <br />when used exclusively to treat opioid abuse, addiction, or overdose. <br />3. For the avoidance of doubt, the Agreement shall not be construed or used as a waiver <br />or limitation of any defense otherwise available to Janssen in any action, and nothing <br />in the Agreement is intended to or shall be construed to prohibit Janssen in any way <br />whatsoever from taking legal or factual positions with regard to any Opioid <br />Product(s) in defense of litigation or other legal proceedings. <br />4. Upon the request of the State of Washington Attorney General, Janssen shall provide <br />the Washington Attorney General with copies of the following, within thirty (30) <br />days of the request: